eGFR: Evidence-Based Ways to Improve This Number

What eGFR Actually Measures (and Why Women Get a Different Result)

EGFR is a calculated estimate of how many milliliters of blood your kidneys clean per minute, adjusted for body surface area. Labs derive it from your serum creatinine, age, and sex using the CKD-EPI 2021 equation, which removed the race adjustment that was standard until 2021. The number does not measure creatinine directly. It converts creatinine into a filtration estimate.

Why the Female Reference Range Is Lower

Creatinine is a byproduct of muscle metabolism. Women carry less skeletal muscle than men on average, so they produce less creatinine at baseline. The same serum creatinine value in a woman and a man of identical age represents different degrees of kidney impairment, which is why the CKD-EPI equation uses sex as an input. Even after adjustment, women with chronic kidney disease (CKD) tend to have lower eGFR values at diagnosis than men while still showing equivalent or worse histological damage on biopsy. This means your result might look "less bad" than it actually is relative to your individual kidney reserve.

How Hormones Shift Your Number Across Life Stages

Estrogen has a direct nephroprotective effect. It modulates the renin-angiotensin-aldosterone system (RAAS), reduces glomerular hypertension, and limits fibrosis in kidney tissue. Data from the Women's Health Initiative showed that postmenopausal women have steeper annual eGFR decline than premenopausal women of similar metabolic health, with the sharpest drop occurring in the first five years after the final menstrual period. During the reproductive years, your eGFR fluctuates slightly across the menstrual cycle, peaking in the luteal phase due to progesterone-driven changes in renal blood flow, though this variation is generally under 5 mL/min and rarely affects clinical interpretation.

PCOS complicates the picture. Women with PCOS have higher rates of hypertension, insulin resistance, and obesity, all independent risk factors for CKD. A 2019 meta-analysis in the Journal of Clinical Endocrinology and Metabolism found that women with PCOS had a significantly higher prevalence of CKD markers, including reduced eGFR and elevated albuminuria, compared with controls.

What a Normal eGFR Range Looks Like

The Kidney Disease Improving Global Outcomes (KDIGO) 2022 guidelines classify CKD by both eGFR (G stages) and albuminuria (A stages). EGFR alone does not define CKD. You need either an eGFR persistently below 60, or evidence of kidney damage (albuminuria, imaging abnormality, or biopsy finding) persisting for at least three months.

The G Stages at a Glance

| Stage | eGFR (mL/min/1.73 m²) | Plain-language meaning | |-------|----------------------|------------------------| | G1 | 90 or above | Normal or high filtration | | G2 | 60-89 | Mildly decreased | | G3a | 45-59 | Mild to moderate decrease | | G3b | 30-44 | Moderate to severe decrease | | G4 | 15-29 | Severely decreased | | G5 | Below 15 | Kidney failure |

A single low reading is not enough for diagnosis. Labs can dip temporarily with dehydration, a high-protein meal the night before the draw, intense exercise, or an acute illness. Repeat the test in two to four weeks under standard conditions before drawing clinical conclusions.

What a High eGFR Means

An eGFR above 90 mL/min/1.73 m² is normal-to-high. Values above 120 can sometimes indicate hyperfiltration, a state where the kidneys are working under excess pressure. Hyperfiltration is seen in early, poorly controlled type 1 or type 2 diabetes, in pregnancy, and in women with a single kidney compensating for the absent one. Hyperfiltration can paradoxically damage nephrons over time, so an eGFR of 130 is not necessarily "better" than 95.

Evidence-Based Ways to Improve or Protect Your eGFR

The strategies below are organized by strength of evidence. Not every intervention works for every cause of kidney disease. Diabetic nephropathy, hypertensive nephropathy, lupus nephritis, and autoimmune causes each respond to different treatments. Identifying the underlying cause matters more than applying a generic "kidney health" protocol.

1. Blood Pressure Control to a Target of 120/80 mmHg or Lower

High blood pressure is the second leading cause of CKD in women after diabetes. The SPRINT trial (9,361 participants) found that intensive systolic BP control to below 120 mmHg reduced the composite cardiovascular endpoint and slowed kidney function decline compared with a target below 140 mmHg. The benefit in the CKD subgroup was real, though the absolute eGFR difference was modest (roughly 1-2 mL/min/1.73 m² per year of aggressive vs. Standard treatment over three years).

For women specifically, the RAAS is modulated by estrogen and progesterone. Blood pressure often improves in the luteal phase and worsens at perimenopause when estrogen fluctuates and aldosterone sensitivity changes. Your provider may need to reassess your antihypertensive regimen at perimenopause rather than keeping doses static from your reproductive years.

2. SGLT2 Inhibitors: The Strongest Pharmacological Evidence for eGFR Preservation

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) are now first-line for CKD regardless of diabetes status, based on landmark trials.

The DAPA-CKD trial (n = 4,304, including people without diabetes) showed that dapagliflozin 10 mg daily reduced the risk of sustained 50% eGFR decline, kidney failure, or renal death by 39% compared with placebo over 2.4 years. The EMPA-KIDNEY trial confirmed empagliflozin 10 mg daily reduced kidney disease progression by 28% in a broad CKD population. Women made up roughly 33% of both trial populations, an evidence gap worth naming: sex-stratified eGFR outcomes from these trials have not been fully published in a way that lets us say definitively that the magnitude of benefit is identical in women. The overall direction of benefit appears consistent.

SGLT2 inhibitors cause a predictable, transient drop in eGFR of 3-5 mL/min/1.73 m² in the first four to eight weeks after starting. This is a hemodynamic effect, not true kidney damage. Do not stop the medication based on this initial dip without nephrology input.

3. GLP-1 Receptor Agonists and Kidney Outcomes

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) were initially studied for cardiovascular outcomes but have shown consistent secondary kidney benefits. The FLOW trial (semaglutide 1 mg weekly, n = 3,533 people with type 2 diabetes and CKD) reported a 24% reduction in kidney disease progression or cardiovascular death. Semaglutide reduced the rate of eGFR decline by approximately 1.16 mL/min/1.73 m² per year more than placebo.

For women using GLP-1 agents for weight management or PCOS-related metabolic disease, the kidney benefit is a meaningful secondary gain. Dosing of semaglutide and liraglutide does not require adjustment based on eGFR, but semaglutide subcutaneous (Ozempic, Wegovy) should be used cautiously in stage G4-G5 disease due to limited data. Oral semaglutide (Rybelsus) absorption depends on gastric conditions rather than renal clearance, so eGFR cutoffs differ slightly.

4. Dietary Protein Intake: How Much Actually Matters

The longstanding recommendation to restrict dietary protein in CKD (0.6-0.8 g/kg/day for non-dialysis CKD) is based on evidence that high protein loads increase glomerular filtration pressure and may accelerate nephron loss. KDIGO 2022 guidelines recommend avoiding high protein intake (above 1.3 g/kg/day) in adults with CKD at risk of progression, while keeping intake at or above 0.8 g/kg/day to prevent malnutrition.

For women, protein needs interact with life stage in ways that matter clinically. Postpartum and lactating women need more protein (1.1-1.3 g/kg/day above pre-pregnancy baseline) for tissue repair and milk production. A woman with stage G3a CKD who is breastfeeding sits in genuine tension between nephrology guidelines and lactation nutritional needs. That requires individualized dietitian input, not a generic restriction.

Plant-dominant protein sources appear to be less nephrotoxic than animal protein gram-for-gram, possibly because they generate less acid load and lower TMAO levels. A 2017 analysis of NHANES data found that higher plant protein intake was associated with lower risk of CKD-related mortality, though observational data cannot prove causation.

5. Sodium Restriction and Fluid Balance

Excess dietary sodium raises blood pressure and increases intraglomerular pressure directly. KDIGO recommends sodium intake below 2 g per day (5 g of salt) for adults with CKD. This target is hard to reach on a standard Western diet, where processed foods account for roughly 70% of sodium intake.

Women with PCOS or premenstrual syndrome often retain more sodium in the luteal phase due to aldosterone and progesterone fluctuations. Tracking sodium becomes more useful when you also track your cycle phase, because what looks like dietary non-adherence might partly be hormonal.

6. Glycemic Control in Diabetic Kidney Disease

Tight glycemic control (HbA1c 6.5-7.5% depending on individual risk) slows the progression of diabetic nephropathy, the single most common cause of CKD in women with type 2 diabetes. The UKPDS 35 study showed that each 1% reduction in mean HbA1c was associated with a 37% reduction in microvascular complications including nephropathy.

Metformin, the foundational medication for type 2 diabetes and a first-line agent in PCOS, requires eGFR monitoring. The FDA label states that metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m² and recommends assessing risk vs. Benefit at eGFR 30-45 mL/min/1.73 m². Many providers hold metformin at eGFR below 30 and reduce the dose at eGFR 30-44. If you are using metformin for PCOS and your eGFR dips during a period of illness or dehydration, hold the medication and recheck rather than continuing through the episode.

7. Weight Management and Obesity-Related Hyperfiltration

Obesity independently causes hyperfiltration, glomerulomegaly, and, over years, a form of secondary focal segmental glomerulosclerosis (FSGS). A 2017 analysis showed that each 1-unit increase in BMI was associated with a 7% increased risk of incident CKD, with effects strongest in women who also had hypertension.

Intentional weight loss of 5-10% of body weight reduces glomerular filtration pressure and can modestly increase eGFR in women with obesity-related hyperfiltration. This is one context where an eGFR rise after an intervention reflects genuine improvement rather than measurement noise.

8. Avoiding Nephrotoxic Medications and Supplements

NSAIDs (ibuprofen, naproxen, diclofenac) reduce prostaglandin-mediated afferent arteriolar dilation and can acutely drop eGFR, a risk that compounds in women who take them regularly for menstrual cramps or endometriosis pain. Regular NSAID use for dysmenorrhea should be discussed openly with your provider if you already have stage G3 CKD or worse. Short-term use around menstruation is lower-risk than daily chronic use, but the conversation still needs to happen.

Certain supplements common in women's health marketing carry real nephrotoxic risk. Aristolochic acid (found in some traditional herbal weight-loss formulas) causes irreversible nephropathy. High-dose vitamin C (above 2 g/day) increases oxalate load and kidney stone risk. Creatine supplementation raises serum creatinine and can falsely lower your calculated eGFR without representing true function loss, a nuance worth flagging if you are an athlete using creatine before a lab draw.

9. Exercise: Type and Dose

Regular aerobic exercise improves blood pressure, insulin sensitivity, and cardiovascular risk, all of which benefit kidney health indirectly. Direct evidence that exercise raises eGFR is thin. A 2019 Cochrane review of exercise in CKD found that exercise improved cardiorespiratory fitness and quality of life in people with CKD but did not demonstrate a consistent significant eGFR improvement compared with usual care. This is an evidence gap, not evidence of no effect.

Intense resistance exercise in the 24-48 hours before a blood draw transiently raises creatinine from muscle breakdown and lowers your calculated eGFR. Schedule your lab draw on a rest day for a more accurate baseline.

Pregnancy, Postpartum, and Lactation: What eGFR Means at These Life Stages

Pregnancy produces a physiological 40-60% rise in glomerular filtration rate by the end of the first trimester. Normal eGFR in pregnancy commonly reaches 130-180 mL/min/1.73 m², meaning that values that would be "normal" outside pregnancy (60-89) may actually reflect significant underlying impairment during pregnancy. Standard CKD-EPI equations were not validated in pregnancy and underestimate GFR in pregnant women. Cystatin C-based or measured GFR (iohexol or inulin clearance) is more accurate in pregnancy.

Women with pre-existing CKD face higher risks in pregnancy: preeclampsia rates are 22-40% in women with stage G3 CKD compared with 3-5% in the general population, according to a 2015 systematic review in the American Journal of Obstetrics and Gynecology. Pregnancy itself can accelerate CKD progression in women with eGFR below 40 at conception. A nephrology and maternal-fetal medicine co-management plan before conception is not optional at that stage.

Drug Safety in CKD During Pregnancy and Lactation

Most medications used to protect kidney function carry restrictions in pregnancy.

• ACE inhibitors and ARBs are the standard of care for proteinuric CKD outside pregnancy but are contraindicated in the second and third trimester due to fetal renal tubular dysplasia and oligohydramnios. They must be switched before conception or immediately on confirmed pregnancy.
• Metformin is classified as relatively low-risk in pregnancy (used in gestational diabetes and PCOS through first trimester in many guidelines) but requires careful eGFR monitoring as pregnancy-related volume shifts can alter renal handling.
• SGLT2 inhibitors are not recommended in pregnancy due to absence of safety data and animal teratogenicity signals. Women of reproductive age on an SGLT2 inhibitor for CKD should use reliable contraception and stop the medication on confirmed pregnancy.
• GLP-1 receptor agonists should be stopped at least two months before attempting conception and are not used in pregnancy or lactation. ACOG has not yet issued a formal guideline specific to GLP-1 use in CKD pregnancy, reflecting a current evidence gap.

During lactation, eGFR typically remains mildly elevated above pre-pregnancy baseline for the first few months postpartum and then returns toward your personal baseline. Postpartum thyroiditis affects up to 10% of women in the first year after delivery and can indirectly affect kidney perfusion through changes in cardiac output; this is one reason a full metabolic panel including eGFR is worth checking at your six-week and six-month postpartum visits if you have any CKD history.

Who This Applies to by Life Stage and Condition

Reproductive Years (18-40)

Women in this group with reduced eGFR most often have lupus nephritis, IgA nephropathy, or CKD secondary to PCOS-related metabolic disease. Blood pressure control, RAAS blockade with reliable contraception if using ACE/ARB, and glycemic control are the priority interventions.

Perimenopause (40s to early 50s)

This is the highest-risk window for eGFR decline acceleration. Estrogen withdrawal raises RAAS activity and blood pressure. An eGFR that was stable at 65 mL/min/1.73 m² at age 42 may trend toward 55 by age 52 even without new risk factors. Annual monitoring becomes quarterly if you have stage G3 CKD entering perimenopause. Whether menopausal hormone therapy (MHT) slows eGFR decline is not yet established in randomized trials specifically designed to answer that question, a clear evidence gap.

Post-Menopause (50s and beyond)

Post-menopause is when CKD incidence peaks in women. Cardiovascular risk and CKD risk are tightly linked in this group. Statin therapy for cardiovascular risk reduction is guideline-supported regardless of CKD stage, and statins do not require eGFR-based dose adjustment in most cases. The KDIGO 2022 CKD guideline recommends statin or statin-plus-ezetimibe therapy in adults with CKD aged 50 and older who are not on dialysis.

When to Refer and What to Watch For

See a nephrologist if:

• eGFR drops more than 5 mL/min/1.73 m² within 12 months or more than 10 mL/min/1.73 m² within five years
• eGFR falls below 30 mL/min/1.73 m² at any point
• You have proteinuria above 300 mg/g creatinine (A3 albuminuria) at any eGFR stage
• You are planning pregnancy with an eGFR below 60
• Your eGFR is unexpectedly low given your age and risk profile (think: autoimmune disease, family history of polycystic kidney disease, history of preeclampsia, prior acute kidney injury)

A single low eGFR triggers a repeat test. Two readings below 60 separated by at least three months confirm stage G3 CKD. At that point, the monitoring schedule is at minimum annual for G3a, every six months for G3b, and every three to four months for G4.